this issue has been discussed on this board before if you do a search. i agree with you that biomarkers that exist for copaxone don't quite measure up to "explaining to a significant degree the pharmacological activity" of the compound, and one is going to have to put more weight on the characterization relative to lovenox. nevertheless Xa/IIa don't fully explain the activity of LMW heparins either, and the biomarkers of copaxone do have some correlation with activity and some are even used by TEVA as manufacturing controls, so it is all relative and a question of degree
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.